Upcoming therapies for heart failure.
Treatment of maladaptive neurohormonal activation in congestive heart failure (CHF) has been successful because basic cardiovascular science findings have been confirmed or dismissed through the use of well-controlled, large-scale clinical trials. It should be no surprise that this exciting approach is evolving toward novel agents and devices directed toward other pathways involved in CHF neurohormonal/cytokine activation. Several of these are in advanced clinical development and are likely to play prominent roles in CHF therapy in the near future.
O'Brien
T X
TX
Cardiology Section of the Department of Medicine, Gazes Cardiac Research Institute, Medical University of South Carolina, Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina, USA.
Brown
A M
AM
D057911:Angiotensin Receptor Antagonists; D002304:Cardiac Pacing, Artificial; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014667:Vasopressins / Q000037:antagonists & inhibitors
D057911:Angiotensin Receptor Antagonists; D014409:Tumor Necrosis Factor-alpha; D014667:Vasopressins